ClinicalTrials.gg
RecruitingNCT06548399Long-IBDUpdated Oct 1, 2026

Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease

An observational study in Inflammatory Bowel Diseases, Crohn's Disease and Ulcerative Colitis, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by McMaster University · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 156 studies in Inflammatory Bowel Diseases with a site in Canada — 35 open to participants now, 50 under way, 6 of them phase 3. Inflammatory Bowel Diseases · Canada.

Planned enrollment
36th of 36
15 · median 157
Started
2024
with 12 others
Observational
36 of 156
9 open now
Primary completion
2027-03
later than 19 of 49 live
Registered
134th of 156
by date
Lead sponsor
7 of 156
McMaster University

Among the 156 studies in Inflammatory Bowel Diseases with a site in Canada, this one is the 36th largest by planned enrollment of the 36 observational ones that give a count, is one of 13 that started in 2024, is one of 36 observational ones, reaches primary completion later than 19 of the 49 other live ones, and was the 134th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

35 of the 156 studies in Inflammatory Bowel Diseases with a site in Canada are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Inflammatory Bowel Diseases with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether the gut bacteria in IBD patients cause ongoing abdominal pain, even when the disease is calm. Many inflammatory bowel disease (IBD) patients have this pain, regardless of whether their disease is active or not. This might be linked to an imbalance in gut bacteria. Certain IBD patients with persistent abdominal pain experience increased sensitivity in their gut due to bacteria producing LPC and LPA. Our goal is to explore the connection between bacterial LPC/LPA levels and symptoms in IBD patients with long-lasting abdominal pain. Additionally, we aim to pinpoint the specific bacteria responsible for producing LPC/LPA, which in turn causes chronic abdominal pain in these patients.

Read the detailed description

The human body is inhabited by a complex community of microbes, collectively referred to as "microbiota". A vast majority of these bacteria are found in the lumen of the gastrontestinal tract (colon, small intestine, stomach and esophagus). Several lines of evidence indicate that changes in microbiota (bacteria) may be involved in the origin of different gastrointestinal diseases, including inflammatory Bowel Disease (IBD), with its two main types: Crohn´s disease and Ulcerative colitis.

Recent data suggest that the gut bacteria have the capability to produce lysophosphatidylcholine (LPC) and its derivative, lysophosphatidic acid (LPA), small lipid molecules that were shown previously to be involved in the genesis and maintenance of chronic pain. The investigators found that these molecules are higher in stool of patients with Inflammatory Bowel Disease (IBD), but it is unclear whether 1) they are produced by gut bacteria, and 2) whether their production underlies chronic pain in patients with IBD.

The purpose of this study is to determine whether the gut bacteria produce LPC and LPA and induce chronic abdominal pain, which is common in many patients with IBD, even when their colitis is in remission (absence of overt gut inflammation).

In this exploratory longitudinal study, the investigators will recruit patients with IBD, aged 18-70 years, of both sexes, with a history of moderate to severe chronic abdominal pain (as defined by their gastroenterologist), which persists during remission of colitis (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin less than 200 μg/g of stool) or while having only mild gut inflammation, defined by either colonoscopy (Endoscopic Mayo score: 0-1 or Simple Endoscopic Score for Crohn's Disease score: 0-10). We will recruit 15 patients with baseline stool LPC less that 200 μg/mg and LPA less than 100 μg/mg levels after first assessment in screening visit. Recruitment will take place at McMaster University IBD clinic (https://www.mcmasteribd.com).

After study participant meets the eligibility criteria and signs the informed consent, stool and urine samples will be collected and abdominal pain scores recorded for 3 weeks. Daily stool and urine samples (first stool of the day and morning (overnight) urine) will be collected, and LPC/LPA measured by ELISA. Abdominal pain will be assessed daily with a visual analogue scale (VAS). In addition, clinical symptoms will be evaluated by PROMIS (GI Belly Pain, Diarrhea, Constipation and Bloating) and DASS-21 questionnaires at the end of each week, as they assess symptoms during the preceding 7 days. Dietary intake will be assessed at the beginning of each week by a 3-day food diary. The clinical surveys will be provided online, using RedCap software and secure servers already operational within McMaster.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn's Disease
  • Ulcerative Colitis

Keywords

  • longitudinal
  • IBD
  • bacteria
  • LPC
  • LPA
  • Chron's disease
  • Ulcerative colitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of IBD: Crohn\'s disease or Ulcerative colitis followed at McMaster University's Gastroenterology Outpatient Clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 and 70 years of age
  • Crohn's disease diagnosis with history of past or current moderate or severe chronic abdominal pain that persist despite colitis being in remission (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin of less than 200 μg/g of stool), or in presence of mild inflammation defined by colonoscopy (Simple Endoscopic Score for Crohn's Disease score: 0-10),
  • Ulcerative colitis diagnosis with history of past or current moderate or severe chronic abdominal pain that persist despite colitis being in remission (absence of overt inflammation on CT or MRI imaging, and baseline fecal calprotectin less than 200 μg/g of stool) or in presence of mild inflammation defined by colonoscopy (Endoscopic Mayo score: 0-1)

Exclusion criteria

Exclusion Criteria:

  • Current acid anti-secretory and antacid medications
  • Antibiotics, antibacterial agents or probiotics, currently, or within the last 8 weeks
  • Current pain treatment with opioids or NSAIDs (acetaminophen is permitted)
  • Alcohol or drug abuse
  • Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Correlation between daily abdominal pain and stool LPC/LPA levels

    Time frame: From enrolment to the end of data/sample collection period at 3 weeks

Secondary outcomes

  1. Correlation between daily abdominal pain and urine LPC/LPA levels

    Time frame: From enrolment to the end of data/sample collection period at 3 weeks

  2. Correlation between daily abdominal pain and abundance of LPC/LPA producing bacteria in the stool

    Time frame: From enrolment to the end of data/sample collection period at 3 weeks

Other outcomes

  1. Associations between weekly average stool LPC/LPA levels and overall gastrointestinal symptoms, anxiety, depression and stress.

    Time frame: From enrolment to the end of data/sample collection period at 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 27 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 12, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Mar 30, 2027
CompletionEst.
May 30, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06548399
Responsible party
Premysl Bercik (Professor, McMaster University) — Principal investigator
First posted
Aug 12, 2024
Start date
Dec 1, 2024
Primary completion
Mar 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Jumanah Alawfi, RD
Contact
alawfij@mcmaster.ca
905 521-2100 ext. 21875
Andrea Nardelli, MD
Contact
nardela@mcmaster.ca
905-521-2100 ext. 21922

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion